In addition, more patients with lymph node metastasis were found in BRCA2 and other CPGs subgroups than the non-GPVs group (60.7% in BRCA2 mutation-carriers and 50.7% in other CPGs mutation-carriers vs. 38.2% in non-carriers, p=1.7×10-6 and 0.04, respectively). This evidence concerns the gene BRCA2 and metastatic malignant neoplasm in the lymph nodes.